Business Context and Reporting Period
This Form 8-K Current Report was filed by PharmaCyte Biotech, Inc. on May 2, 2017, regarding events occurring on May 1, 2017. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity data. The only financial figures disclosed relate to the compensation package for the newly appointed director:
- Quarterly Cash Retainer: $12,500 per calendar quarter.
- Annual Equity Grant: 250,000 shares of restricted common stock.
- Annual Option Grant: Option to purchase 250,000 shares of restricted common stock.
- Option Exercise Price: $0.0734 per share (fair market value on the date of grant).
Material Changes
The material change reported is the appointment of Thomas C. K. Yuen to the Board of Directors. This appointment fills a vacancy created by the departure of certain board members in October 2014. The appointment was accompanied by a new Letter Agreement outlining the director's compensation and equity incentives.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. The document focuses strictly on the execution of the director appointment and the associated compensatory arrangements. The Shares and Options granted were fully vested on the date of the grant (May 1, 2017).
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the dilution impact of the 250,000 annual share grant and 250,000 option grant.
- Confirm the current fair market value of the stock relative to the $0.0734 exercise price to evaluate the intrinsic value of the option grant.
- Review the full text of the Letter Agreement (Exhibit 10.1) for any additional terms, restrictions, or termination clauses not summarized in the 8-K.
- Check subsequent filings to confirm if Mr. Yuen has assumed any additional officer roles beyond the Board appointment.